AlloVir Inc. (ALVR): Price and Financial Metrics

AlloVir Inc. (ALVR): $3.89

-0.07 (-1.77%)

POWR Rating

Component Grades













Add ALVR to Watchlist
Sign Up

Industry: Biotech



in industry

ALVR Stock Price Chart Interactive Chart >

Price chart for ALVR

ALVR Price/Volume Stats

Current price $3.89 52-week high $26.41
Prev. close $3.96 52-week low $3.21
Day low $3.68 Volume 448,100
Day high $4.02 Avg. volume 1,276,923
50-day MA $5.89 Dividend yield N/A
200-day MA $14.13 Market Cap 254.48M

AlloVir Inc. (ALVR) Company Bio

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

ALVR Latest News Stream

Event/Time News Detail
Loading, please wait...

ALVR Latest Social Stream

Loading social stream, please wait...

View Full ALVR Social Stream

Latest ALVR News From Around the Web

Below are the latest news stories about Allovir Inc that investors may wish to consider to help them evaluate ALVR as an investment opportunity.

Rate - Zacks Investment Research Lowers AlloVir to Sell

Zacks Investment Research cut shares of AlloVir from a hold rating to a sell rating in a report published on Friday morning, reports. According to Zacks, “AlloVir…

Business Mag | February 14, 2022

AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. A live webcast of the fireside chat will be available on the Investors & Press section of the AlloVir website at An archived replay will be availa

Business Wire | February 11, 2022

Recap: AlloVir Q4 Earnings

AlloVir (NASDAQ: ALVR ) reported its Q4 earnings results on Thursday, February 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Check out this: Insiders Buy Over $43M Of 4 Stocks Earnings AlloVir … Full story available on

Benzinga | February 10, 2022

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections

Business Wire | February 10, 2022

AlloVir GAAP EPS of -$2.74 misses by $0.10

AlloVir press release (ALVR): FY GAAP EPS of -$2.74 misses by $0.10.As of December 31, 2021, company had cash, cash equivalents and marketable securities of $248.1 million, compared…

Seeking Alpha | February 10, 2022

Read More 'ALVR' Stories Here

ALVR Price Returns

1-mo -28.23%
3-mo -54.24%
6-mo -79.82%
1-year -81.97%
3-year N/A
5-year N/A
YTD -69.94%
2021 -66.34%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7953 seconds.